Why is Gland Pharma falling/rising?

As of 21-Jul, Gland Pharma Ltd's stock price is currently at 2,010.10, reflecting an increase of 16.1 points or 0.81%. The stock has shown strong performance recently, with a one-week return of +6.43% and a one-month return of +16.75%, significantly outperforming the Sensex, which has seen a slight decline of -0.06% over the same week and -0.25% over the month. Despite a day’s low of Rs 1950.4, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend. However, there has been a notable decrease in investor participation, with delivery volume dropping by -27.12% compared to the 5-day average. The company benefits from a low debt-to-equity ratio and high institutional holdings at 40.18%, suggesting strong confidence from institutional investors, which may contribute to the stock's upward movement.
In the broader market context, Gland Pharma's recent performance contrasts sharply with the Sensex, which has not only underperformed in the short term but also in the year-to-date comparison, where Gland Pharma has a return of +12.38% compared to the Sensex's +5.20%. This indicates that Gland Pharma is gaining traction among investors, likely due to its solid fundamentals and institutional backing, even as overall market conditions remain challenging. The stock's ability to outperform the sector by 1.13% today further underscores its relative strength in the current market environment.